

REVIEW

Insights into the pharmacological relevance of lysophospholipid receptors

Tetsuji Mutoh^{1,2}, Richard Rivera¹ and Jerold Chun¹

¹Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA, USA, and ²Gunma Kokusai Academy, Gunma, Japan

Correspondence

Jerold Chun, The Scripps Research Institute, 10550 N. Torrey Pines Rd., DNC 118, La Jolla, CA, USA. E-mail: jchun@scripps.edu

Keywords

G protein-coupled receptors; lysophospholipids; multiple sclerosis; hearing loss; neuropathic pain; embryo implantation; molecular pharmacology; FTY720 (fingolimod)

Received

2 March 2011

Revised

22 July 2011

Accepted

23 July 2011

The discovery of lysophospholipid (LP) 7-transmembrane, G protein-coupled receptors (GPCRs) that began in the 1990s, together with research into the functional roles of the major LPs known as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), have opened new research avenues into their biological processes and mechanisms. Major examples of LP signalling effects include embryogenesis, nervous system development, vascular development, uterine implantation, immune cell trafficking, and inflammatory reactions. LP signalling also influences the pathophysiology of many diseases including cancer, autoimmune and inflammatory diseases, which indicate that LP receptors may be attractive targets for pharmacological therapies. A key example of such a therapeutic agent is the S1P receptor modulator FTY720, which upon phosphorylation and continued drug exposure, acts as an S1P receptor functional antagonist. This compound (also known as fingolimod or Gilenya) has recently been approved by the FDA for the treatment of relapsing forms of multiple sclerosis. Continued basic and translational research on LP signalling should provide novel insights into both basic biological mechanisms, as well as novel therapeutic approaches to combat a range of human diseases.

Abbreviations

GPCR, G protein-coupled receptor; IUPHAR, International Union of Basic and Clinical Pharmacology; LPA, lysophosphatidic acid; LPs, lysophospholipids; S1P, sphingosine 1-phosphate; SMC, smooth muscle cells; TCM, central memory T cell; TEM, effector memory T cells

Introduction

Lysophospholipids are cell membrane lipid derivatives that also act as extracellular signals, joining other lipid mediators that include prostaglandins, leukotrienes, platelet-activating factors, and endocannabinoids. Lysophospholipids (LP) are small (around 400 Da), 3-carbon backbone phospholipids derived from glycerophospholipids or sphingolipids, containing a single carbon chain of varied length and saturation. Examples of LPs include LPA (lysophosphatidic acid), S1P (sphingosine 1-phosphate), LPC (lysophosphatidylcholine), SPC (sphingosylphosphorylcho-

line), LPS (lysophosphatidylserine) and LPE (lysophosphatidylethanolamine) (Figure 1). This review will focus on LPA and S1P, both of which have been analysed extensively with respect to both ligand and receptor. However, it is notable that other LPs likely have distinct physiologies that remain to be elucidated, such as LPC, that is present at high concentration in blood (several hundred μ M) (Croset *et al.*, 2000), and has been reported to modulate cardiac potassium channels through several G proteins (Ding *et al.*, 2011), suggesting involvement of one or more unidentified receptors. LPA and S1P have well documented *in vivo* functions mediated by cognate G protein-coupled receptors




Figure 1

The molecular structure of major lysophospholipids. Space-filling molecular models and structural formulas of LPA, S1P, LPC, SPC, LPS and LPE and some major analogues are shown. High-affinity LP receptors are indicated in parentheses under the name of each ligand.

(GPCRs), despite their comparatively low concentrations (low μM range) (Okajima, 2002; Aoki, 2004). LPs are usually bound to lipoproteins *in vivo*. Serum LPA is bound by albumin, gelsolin and other proteins (Moolenaar *et al.*, 2004). S1P is bound by HDL and albumin (Okajima, 2002; Levkau *et al.*, 2004; Nofer *et al.*, 2004; Theilmeier *et al.*, 2006; Sato *et al.*, 2007). These lipoproteins stabilize LPs in the hydrophilic environment and possibly protect them from overly rapid degradation. LPs in isolation are unstable and are rapidly degraded within a few hours or less *in vivo* (Pages *et al.*, 2001). Dephosphorylation by lipid phosphate phosphatases (LPPs) inactivates LPA and S1P by conversion to monoacylglycerol (MAG) and sphingosine respectively (Morris *et al.*, 2009). S1P can be permanently degraded to

hexadecanal and phosphoethanolamine by S1P lyase (Brindley and Pilquill, 2009). LPA can also be converted to phosphatidic acid by an LPA acyltransferase, and the long chain fatty acyl group can be hydrolysed by lysophospholipases (Lin *et al.*, 2010). Ligand availability, concentration and half-life may influence cellular responses mediated by LP receptors. The stabilization effect of lipoproteins is currently being studied (Moumtzi *et al.*, 2007).

Initially, LPs were shown to be precursors and metabolites in the *de novo* biosynthesis of phospholipids. It was previously thought that the effect of LPs and their mechanisms of action were largely non-specific. However, other bioactive properties were subsequently discovered. For instance, LPA was shown to function as an anti-hypertensive agent (Sen

et al., 1968; Tokumura *et al.*, 1978). LPA also acts as a cell growth and motility factor present in serum, and the signalling cascades mediated by LPA were shown to involve G proteins (van Corven *et al.*, 1989), suggesting that LPA's effects were mediated through GPCRs, although other GPCR-independent mechanisms were also possible considering the high concentrations often employed combined with a lack of identified receptors.

The first LP receptor was cloned from mouse brain cDNA by degenerate PCR with primers designed against GPCRs (Hecht *et al.*, 1996). This receptor, originally designated VZG-1, and now called LPA₁, was the first LP receptor discovered. Within several years of this initial report, several members of an orphan GPCR receptor family, called 'endothelial differentiation genes (Edg)', as well as other names were identified as GPCRs for both LPA and S1P (An *et al.*, 1997; Lee *et al.*, 1998; Im *et al.*, 2000a; Van Brocklyn *et al.*, 2000; Ishii *et al.*, 2004). For the LPA receptors, another group of less similar GPCR genes have also been identified (Noguchi *et al.*, 2003; Kotarsky *et al.*, 2006; Lee *et al.*, 2006). This latter group is more closely related to the family of P2Y purinergic receptor genes, indicating that LPA receptors have evolved via two distinct lineages in the rhodopsin GPCR family. To date, 11 *bona fide* LP receptors have been reported, 6 for LPA (LPA₁₋₆) and 5 for S1P (S1P₁₋₅), with additional putative LP G protein-coupled receptors (GPCRs) existing in the literature (Anliker and Chun, 2004b; Ishii *et al.*, 2004; Lee *et al.*, 2006; Rivera and Chun, 2008). All of these LP receptors are GPCRs capable of interacting with a number of heterotrimeric G proteins. The current nomenclature reflects the receptor's cognate ligand and chronological order of the relevant receptor's identification (Chun *et al.*, 2010) (Table 1). Protein receptor names are LPA₁₋₆ and S1P₁₋₅. Gene names for humans are *LPAR1-6* and *S1PR1-5*, or, for mice, *Lpar1-6* and *S1pr1-5* (Chun *et al.*, 2010). This nomenclature will be used throughout this review.

The synthesis of lipid mediators and subsequent receptor activation is tightly regulated under normal physiological

conditions, and enzyme and/or receptor dysfunction can lead to a variety of disease conditions. LP signalling itself can also influence other signalling pathways, such as signalling crosstalk with S1P, and other pro-angiogenic growth factors, such as VEGF, EGF, IGF, PDGF, bFGF and IL-8 have been reported (Schwartz *et al.*, 2001; Spiegel and Milstien, 2003; Pyne *et al.*, 2007). Thus, the manipulation of lipid mediator signalling through enzyme inhibitors or receptor antagonists and agonists has great potential as a therapeutic approach to disease. This review summarizes our current knowledge of LP lipid mediators and the function of their cognate receptors. It also discusses the effects of genetic ablation or pharmacological inhibition of enzyme or receptor function on various pathophysiological processes. We will also discuss the normal physiological functions of LPA and S1P mediated by their cognate receptors and discuss diseases associated with these bioactive LP molecules and their pharmaceutical application or potential.

LP Receptors and GPCRs

LP receptor genes are distributed throughout the genome. The coding regions for the LPA receptors in the genomes of humans and mice are found in multiple exons (LPA_{1-3,6}) or single exons (LPA₄ and LPA₅), while the coding region of each of the 5 S1P receptors is contained within a single exon, with only non-coding exon(s) upstream (Contos and Chun, 2001; Contos *et al.*, 2000b; 2002). Several structural characteristics are shared between LPA and S1P receptors, including an extracellular N-terminus, seven α -helical transmembrane helices, and an intracellular C-terminus (Pierce *et al.*, 2002). No formal structural data have been reported for this family of GPCRs, although non-G protein binding, fusion-protein structures should be available for some receptors in the near future.

LP receptors each have a heterogeneous spatiotemporal gene expression pattern and the same cell may express mul-

Table 1

Nomenclature of lysophospholipid receptors

IUPHAR nomenclature	Chromosomal location (Human)	Natural agonist ligand	Human gene name	Mouse gene name
LPA ₁	9q32	LPA	<i>LPAR1</i>	<i>Lpar1</i>
LPA ₂	19p12	LPA	<i>LPAR2</i>	<i>Lpar2</i>
LPA ₃	1p22.3–p31.1	LPA	<i>LPAR3</i>	<i>Lpar3</i>
LPA ₄	Xq13–q21.1	LPA	<i>LPAR4</i>	<i>Lpar4</i>
LPA ₅	12p 13.31	LPA	<i>LPAR5</i>	<i>Lpar5</i>
LPA ₆	13q14	LPA	<i>LPAR6</i>	<i>Lpar6</i>
S1P ₁	1p21	S1P > SPC	<i>S1PR1</i>	<i>S1pr1</i>
S1P ₂	19p13.2	S1P > SPC	<i>S1PR2</i>	<i>S1pr2</i>
S1P ₃	9q22.1–q22.2	S1P > SPC	<i>S1PR3</i>	<i>S1pr3</i>
S1P ₄	19p13.3	S1P > SPC	<i>S1PR4</i>	<i>S1pr4</i>
S1P ₅	19p13.2	S1P > SPC	<i>S1PR5</i>	<i>S1pr5</i>

tipic receptors. These data were derived by examining mRNA for the presence of specific receptor transcripts and combined with functional assays. Notably, no antibodies or antisera have been clearly proven for use in immunohistochemical studies of native proteins, although many can identify over-expressed proteins in cell lines. Some reports have suggested a nuclear localizing protein fraction of LPA₁, but more physiological studies are still needed to elucidate the biological relevance of this fraction (Gobeil *et al.*, 2006).

LPA and S1P receptors couple to heterotrimeric G proteins, which consist of a α and associated $\beta\gamma$ subunits. The heterotrimeric G proteins are thought to bind to the inner surface of the cell membrane. One receptor may couple to several different types of α protein subunits to form a complex signalling network (Figure 2). LPA_{1,2,4,5,6} and S1P₂₋₅ all signal through $\alpha_{12/13}$ to activate RhoA, a member of the family of Rho GTPases. LPA₁₋₅ and S1P_{2,3} couple to $\alpha_{q/11}$ to activate phospholipase C (PLC). LPA_{1-4,6} and S1P₁₋₅ also couple with α_i to activate PLC, Ras, phosphoinositide-3 Kinase (PI3K), and to inhibit adenylyl cyclase (AC), but LPA₄ can also couple to α_s to activate AC (Etienne-Manneville and Hall, 2002; Neves *et al.*, 2002; Chun *et al.*, 2010). When a ligand binds to a receptor, it exchanges GDP for GTP on the α subunit, and then α -GTP and $\beta\gamma$ can activate the effector molecule complex for each signalling cascade. The desensitization of receptors is probably mediated by known mechanisms in other systems including phosphorylation of GPCRs by kinases and/or an uncoupling from G proteins by

arrestins, followed by receptor internalization, recycling and/or degradation (Lefkowitz and Shenoy, 2005).

Endogenous regulation of LPA and S1P in vivo

It was previously thought that the main source of lysophospholipids was from blood. Reported concentrations of LPA and S1P vary in the literature, however most publications report around 1000 nM (200–5000 nM) in blood, and 0.2–100 nmol·g⁻¹ in tissues under basal conditions (Das and Hajra, 1989; Eichholtz *et al.*, 1993; Olivera *et al.*, 1994; Yatomi *et al.*, 1997; Murata *et al.*, 2000; Min *et al.*, 2002; Okajima, 2002; Aoki, 2004; Berdyshev *et al.*, 2005; Bielawski *et al.*, 2006). Platelets contain large amounts of LPA and S1P, both of which can be released following platelet activation (Benton *et al.*, 1982; Yatomi *et al.*, 1997). For this reason, it was believed that platelets were the major source of S1P. However, it has been shown that erythrocytes can synthesize S1P by enzymatic pathways (Stoffel *et al.*, 1970), and it is now clear that sphingosine kinases (SPHKs) present in erythrocytes are responsible for S1P in blood (Pappu *et al.*, 2007). In addition, it has been shown that erythrocytes are able to import and store S1P, which can then be actively released upon stimulation (Hanel *et al.*, 2007). It was also believed that LPA in blood is mainly derived from activated platelets;




Figure 2

The network of LPA and S1P signalling through G protein-coupled receptors. Each LPA and S1P receptor couples to specific classes of G proteins. Ligand-binding activates or inhibits downstream second messenger molecules, and the most prominent cellular effects are illustrated. *Rock*, Rho-associated kinase; *Srf*, serum response factor; *IP₃*, inositol 1,4,5-trisphosphate; *PLC*, phospholipase C; *DAG*, diacylglycerol; *PKC*, protein kinase C; *MAPK*, mitogen-activated protein kinase; *PI3K*, phosphoinositide 3-kinase; *DAG*, diacylglycerol.

however, it was reported that an LPA producing enzyme, lysophospholipase D (lysoPLD) in plasma, may also contribute to the total amount of LPA found in blood (Aoki, 2004). The plasma lysoPLD activity was directly measured, and half of this activity is attributed to autotaxin (ATX), one of the major lysoPLDs (Tanaka *et al.*, 2006). In addition to the aforementioned pathway, there might be local LP synthesis in specific tissues. For example, the highest expression of ATX is found in the floor plate of the developing embryo and in the choroid plexus and osteoblasts throughout development (Bachner *et al.*, 1999). Neurons are also a potential source of LPA in the developing brain, as nanomolar concentrations of LPA are found in conditioned medium from embryonic brain primary cultures as estimated in a biological activity assay (Fukushima *et al.*, 2000).

As noted above, there is a wide concentration range of LPA and S1P reported in both blood and tissues. Possible reasons for the differences in concentration may include differences in platelet activation during blood collection, the presence or absence of catabolic enzymes in different tissues and the potential conversion of LPC to LPA by ATX. The inherently sticky nature of LPA also makes it particularly difficult to quantify, especially when levels are already low. LPA is also difficult to extract and differences in the pH of the extraction buffer can produce dramatic differences in sample recovery. It is also possible that LPA and S1P may vary with age, gender or strains of mice used in experiments.

As signalling mediators *in vivo*, the production and degradation of lysophospholipids is tightly controlled. LPs are produced by multi-step enzymatic pathways that are initiated by the de-esterification of membrane phospholipids. The metabolism of LPA has been partially characterized and involves a number of convergent biosynthetic pathways and enzymes of varied specificity (Meyer zu Heringdorf and Jakobs, 2007). To date, lysoPLD, ATX, phospholipase A1 (PLA1), phospholipase A2 (PLA2) and acylglycerol kinase (AGK) are enzymes reported to be involved in LP synthesis (Chun and Rosen, 2006). These enzymes, through multiple pathways, are responsible for LPA production (Meyer zu Heringdorf and Jakobs, 2007).

S1P metabolism involves a number of specific and highly conserved enzymes (Saba and Hla, 2004). Two SPHK isoforms, SPHK1 and SPHK 2, produce S1P from sphingosine (Kohama *et al.*, 1998; Liu *et al.*, 2000). Recently, it was shown by specific genetic removal of SPHK1 and 2 in erythrocytes that these cells are the major source of S1P in blood (Pappu *et al.*, 2007). SPHK activity is not only present in blood, but also in most mouse tissues (with high activity in thymus and lung) (Fukuda *et al.*, 2003).

The duration and strength of LP signalling likely depends, at least locally, on the activity of synthetic and degradative enzymes and their localization relative to the LP receptors. For example, it has been reported that S1P lyase (SPL) has an important role in maintaining a steep gradient of S1P between blood and tissues, which in part controls lymphocyte localization within lymphoid organs, particularly within lymph nodes where a low-to-high gradient exists in moving from the parenchyma to the efferent lymphatics (Schwab *et al.*, 2005; Schwab and Cyster, 2007). The fine distribution and potential LP gradients in other tissues remain to be elucidated. Pharmacological and molecular manipulation of LP

metabolic enzyme activity is also an intriguing approach for cancer therapy or other clinical treatments.

LP receptors and clinical relevance

LPA₁

In adult tissues, LPA₁ shows broad gene expression, with mRNA present in brain, lung, heart, uterus, and other organs of both human and mouse (Choi *et al.*, 2010). Expression of the mouse homologue, *Lpar1*, is more spatially restricted during embryonic development, and is enriched in the brain (Table 2). *Lpar1* was initially called 'ventricular zone gene-1 (Vzg-1)' because of its enrichment in the neural progenitor zone of the mouse embryonic cerebral cortex, the 'ventricular zone' (Hecht *et al.*, 1996). The effects of *Lpar1* gene deletion are seen in studies of the CNS (Contos *et al.*, 2000a,b; Kingsbury *et al.*, 2003; Estivill-Torrus *et al.*, 2008; Matas-Rico *et al.*, 2008; Santin *et al.*, 2009; Castilla-Ortega *et al.*, 2010; Dubin *et al.*, 2010). Furthermore, the deletion of *Lpar1* in mice causes a reduction in litter size with 50% perinatal death (Contos *et al.*, 2000a,b; 2002). Intrathecal injection of LPA, but not S1P, initiates behavioural, morphological and biochemical symptoms of neuropathic pain via an LPA₁-mediated Rho/Rho-kinase (Inoue *et al.*, 2004; 2006; 2008). LPC conversion to LPA by ATX is necessary for these processes *in vivo* (Nagai *et al.*, 2010). LPA signalling modulation may be relevant to some forms of neuropathic pain, an area of significant, unmet medical need (Dworkin *et al.*, 2007). LPA₁ has also been linked to multiple disease processes, including cancer (Hama *et al.*, 2004), fibrosis in kidney (Pradere *et al.*, 2007) and lung (Tager *et al.*, 2008), and male infertility (Ye *et al.*, 2008), in conjunction with loss of other LPA receptors. Recent data has identified LPA₁ signalling as a mediator of hypoxic damage in the fetal brain (Herr *et al.*, 2011) and in the initiation of fetal hydrocephalus (Yung *et al.*, 2011).

LPA₂

LPA₂ has relatively high gene expression in human testis and leukocytes and moderate expression in prostate, spleen, thymus, and pancreas. Compared to the expression pattern of LPA₁, LPA₂ has a more restricted spatiotemporal expression pattern (An *et al.*, 1998; Contos *et al.*, 2000b; Choi *et al.*, 2010). In mice, *Lpar2* is highly expressed in kidney, uterus and testis, and moderately expressed in lung while lower expression levels are found in stomach, spleen, thymus, brain and heart (Contos and Chun, 2000; Anliker and Chun, 2004a). Expression is also detected in embryonic brain but decreases within a week after birth (Contos *et al.*, 2000b). In several cancer cell types, aberrant expression of LPA₂ has been reported, suggesting a possible tumour-promoting role for LPA₂ (Goetzl *et al.*, 1999a; Contos *et al.*, 2000b; Schulte *et al.*, 2001; Kitayama *et al.*, 2004; Shida *et al.*, 2004; Yamashita *et al.*, 2006; Hope *et al.*, 2009). Constitutive loss of *Lpar2* in mice does not cause a grossly abnormal phenotype. However, in combination with deletion of other LPA receptors, reproductive defects resulting from a decrease in germ cell survival are apparent in male mice (Ye *et al.*, 2008). In *ex vivo* experiments, this receptor is

Table 2

Distribution and key functions of LP receptor subtypes

Receptor	mRNA distribution	Key functions
LPA ₁	Widely expressed, including in the CNS	Vasculogenesis/angiogenesis Neural cell migration/function Nerve conduction Cell migration
LPA ₂	Lymphocytes Testis	
LPA ₃	Uterus	Embryo implantation
LPA ₄	Ovary, thymus	Cell migration
LPA ₅	Dorsal root ganglion, Thymus, spleen	Unknown
LPA ₆	Intestinal mucosa Scalp hair follicles Skin	Maintenance of human hair growth
S1P ₁	Widely expressed (high expression on lymphocytes, neural cells, and vasculature)	Lymphocyte egress from secondary lymphoid organs Neural cell migration/function Embryonic development of cardiovascular and nervous systems Blood vessel formation Endothelial barrier function
S1P ₂	Widely expressed	Vascular tone Endothelial barrier function Inner ear maintenance affecting hearing and balance Endothelial barrier function Nerve conduction
S1P ₃	Widely expressed, including the CNS (neural cells/astrocytes) and the endothelium	Endothelial barrier function Neural cell migration/function
S1P ₄	Lymphocytes	Unknown
S1P ₅	Oligodendrocytes NK cells	Oligodendrocyte function Natural killer cell migration

also partially responsible for neural progenitor cell intracellular calcium responses, LPA-induced cortical folding (Kingsbury *et al.*, 2003; Dubin *et al.*, 2010), and contributes to synaptic functions in slice cultures derived from the adult CNS (Trimbuch *et al.*, 2009). A reduced incidence of tumour formation in LPA₂ deficient mice in a mouse model of colitis-associated cancer demonstrates a link to this form of cancer (Lin *et al.*, 2009). In addition, reduced eosinophil infiltration and prostaglandin E₂ levels in the lung fluid of *Lpar2* heterozygous antigen-challenged mice compared with that of control mice suggests that *Lpar2* plays a role in proinflammatory responses (Zhao *et al.*, 2009).

LPA₃

LPA₃ gene expression is broad in human tissues with transcripts present in heart, testis, prostate, pancreas, lung and

ovary (Bandoh *et al.*, 1999; Im *et al.*, 2000b). In mice, *Lpar3* is most abundant in uterus, testis, kidney, lung, stomach, spleen, brain and thymus (Contos *et al.*, 2000b).

Interestingly, in the murine uterus, *Lpar3* mRNA is exclusively expressed in the luminal endometrial epithelium at a crucial time in the embryo implantation window (Ye *et al.*, 2005; Hama *et al.*, 2007; Ye, 2008; Ye and Chun, 2010). *Lpar3* expression appears to be positively and negatively regulated by progesterone and oestrogen and plays a critical role in blastocyst implantation and proper embryo spacing through COX-2, which generates prostaglandins (PGs) E₂ and I₂ (Shah and Catt, 2005; Ye *et al.*, 2005; Hama *et al.*, 2006; Hama *et al.*, 2007). It was recently reported that the expression of several matrix metalloproteases are reduced in the *Lpar3* deficient uterus, which may lead to abnormal collagen subtype turnover and improper extracel-

lular matrix remodelling which may also contribute to the observed implantation defect (Diao *et al.*, 2010).

LPA₄

LPA₄ mRNA is more ubiquitously expressed than other LPA receptors; however, it is highly abundant in both human and mouse ovary (Noguchi *et al.*, 2003). In mice, *Lpar4* is also expressed in heart, skin, thymus, developing brain and embryonic fibroblasts (Lee *et al.*, 2007a; 2008). Whole mount *in situ* hybridization confirmed expression in the developing brain, as well as in limb buds, somites and facial processes (Ohuchi *et al.*, 2008). Gene deletion studies in mice show that *Lpar4* can affect embryonic viability; however, this effect appears to be dependent on genetic background (Lee *et al.*, 2008; Sumida *et al.*, 2010). The identified partially penetrant effect on embryonic lethality is due to a failure of cellular recruitment to the developing blood and lymphatic vessels (Sumida *et al.*, 2010).

Mouse embryo fibroblast (MEF) cells isolated from *Lpar4* deficient mice are hypersensitive to LPA-induced cell motility (Lee *et al.*, 2008). This result indicates that *Lpar4* plays an inhibitory role in LPA-dependent migratory responses. This inhibitory effect was reported to inhibit LPA-induced migratory effects mediated through *Lpar1*. Interestingly, a human cancer cell line ectopically expressing *Lpar4* was prevented from invading a Matrigel Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) (Lee *et al.*, 2008).

LPA₅

In humans, gene expression for LPA₅ is observed in spleen, heart, small intestine, placenta, liver and colon. *Lpar5* is relatively broadly expressed in murine tissues, including embryonic brain, small intestine, skin, spleen, stomach, thymus, lung, heart, liver and embryonic stem cells (Kotarsky *et al.*, 2006; Lee *et al.*, 2006). In addition to LPA, farnesyl pyrophosphate (FPP) and N-arachidonylglycine (NAG) have been reported as LPA₅ ligands (Oh *et al.*, 2008). However, independent studies gave support to LPA₅ as being a legitimate LPA receptor (Williams *et al.*, 2009; Yin *et al.*, 2009). To date, constitutive *Lpar5* gene knockout mice have not been reported. However, expression in immune tissues and dorsal root ganglion suggests a role for *Lpar5* in these tissues (Kotarsky *et al.*, 2006; Lee *et al.*, 2006; Oh *et al.*, 2008).

LPA₆

The orphan receptor P2Y₅ was recently supported as a legitimate sixth LPA receptor and designated as LPA₆ by the International Union of Basic and Clinical Pharmacology (IUPHAR) committee on the basis of the emerging literature (Lee *et al.*, 2007b; Pasternack *et al.*, 2008; Yanagida *et al.*, 2009; Chun *et al.*, 2010). LPA₆ is more closely related to LPA₄ and LPA₅, which are members of the purinoreceptor (P2Y) family of receptors. Its gene structure is that of a nested gene located within intron 17 of the retinoblastoma gene, and it was reported that 2-acyl-LPA rather than 1-acyl-LPA is the preferred ligand of LPA₆ (Yanagida *et al.*, 2009). It is noteworthy that homozygous inactivation of LPA₆ has been implicated in bladder cancer development through unclear mechanisms that may reduce the activity of the tumour suppressor gene, RB1 (Lee *et al.*, 2007b). Human genetic studies indicate that

LPA₆ influences forms of human hair growth (Pasternack *et al.*, 2008; Shinkuma *et al.*, 2010). Gene targeting of *Lpar6* in mice has not been reported, but loss of the receptor may reflect the human hair-growth phenotype.

S1P₁

S1P₁ gene expression is observed in many tissues, with abundance in spleen, brain, heart, lung, adipose tissues, liver, thymus, kidney and skeletal muscle (Zhang *et al.*, 1999; Ishii *et al.*, 2001). Mice engineered to express the beta-galactosidase gene knocked into the *S1pr1* locus show that *S1pr1* protein exists in brain, lung, spleen, heart, vasculature and kidney in adult mice (Chae *et al.*, 2004). In humans, lymphocytes/leukocytes also strongly express S1P₁ (Balthasar *et al.*, 2006).

Constitutive S1P₁-null mice have severe defects in vascular maturation, and die between E12.5 to E14.5 *in utero* because of haemorrhaging (Liu *et al.*, 2000). Endothelial cell-specific deletion of S1P₁ showed that this abnormality was due to a maturation defect in vascular endothelial cells (Allende *et al.*, 2003). S1P₁ expression is localized to myocytes and perivascular SMCs, and bradycardia and hypertension in primates, including humans, is driven by S1P₁ activation (Brinkmann *et al.*, 2010; Chun *et al.*, 2010).

T cell-specific deletion showed that S1P₁ is crucial for egress of mature T cells from the thymus to the periphery (Allende *et al.*, 2004a). S1P₁ expression on lymphocytes also plays a profound role in the control of lymphocyte recirculation. Elegant studies with S1P₁ conditional or SPHK knock-out mice showed that S1P₁ and S1P are necessary for the egress of thymocytes from the thymus and for egress of T and B cells from lymphoid tissues (Brinkmann *et al.*, 2004; Matloubian *et al.*, 2004; Schwab and Cyster, 2007).

The proper S1P gradient between efferent lymphatics and lymph node, together with lymphocyte receptor expression, has been proposed to be important for lymphocyte migration (Schwab *et al.*, 2005). It has been demonstrated that S1P stimulates migration of naive T-cells via S1P₁. Following activation, T-cells temporarily suppress receptor expression which results in the loss of the S1P mediated migration response and retention of T cells in lymphoid organs. Terminally differentiated effector T-cells then up-regulate S1P₁ to egress from lymph nodes (Graeler and Goetzl, 2002; Matloubian *et al.*, 2004; Schwab and Cyster, 2007).

FTY720, a precursor compound that upon *in vivo* phosphorylation acts acutely as an S1P receptor agonist, but chronically as a functional antagonist, has been shown to produce selective retention of T cells (and B-cells) in peripheral lymphoid organs. Several reports have shown that FTY720 is phosphorylated *in vivo* by SPHK2 but not SPHK1 to produce FTY720-P (Allende *et al.*, 2004b; Kharel *et al.*, 2005), and this phosphorylated form inhibits T and B-cell egress from lymph nodes by modulating S1P signalling (Zemann *et al.*, 2006; Schwab and Cyster, 2007). In a recent study involving patients with relapsing MS, FTY720 was found to prevent the egress of CCR7-positive naive T cells and central memory T cells (TCM) from the lymph nodes, but not CCR7-negative effector memory T cells (TEMs) (Mehling *et al.*, 2008; Brinkmann *et al.*, 2010). Because FTY720 does not generally impair lymphocyte proliferation and/or functions, it is distinct from classical immunosuppressive therapies that are

accompanied by opportunistic infections and cancers (Gardell *et al.*, 2006; Rivera and Chun, 2007). Interestingly, in experimental autoimmune encephalomyelitis (EAE), a mouse MS model, nervous system specific-deletion of S1P₁ – particularly from astrocytes – attenuates FTY720 efficacy suggesting the possibility of a non-immunological target for S1P-related MS therapies (Choi *et al.*, 2011).

S1P₂

S1pr2 is abundantly expressed in the lung and heart, but less so in the brain of adult mice and rats (Okazaki *et al.*, 1993; Zhang *et al.*, 1999). However, during embryonic development, *S1pr2* is prominently expressed in the brain (MacLennan *et al.*, 1994).

S1P₂-null mice show a progressive loss of hearing and balance due to degeneration of vestibular and cochlear hair cells (MacLennan *et al.*, 2006; Herr *et al.*, 2007; Kono *et al.*, 2007). This suggests that it may be possible to prevent the degeneration of hair cells with a selective S1P signalling modulator. These studies are ongoing, and may offer novel treatment modalities for the prevention of age-related and ototoxic hearing loss.

S1P₂-null mutants in the C57Bl/6J background have also been reported to show electrophysiological defects and develop seizures (MacLennan *et al.*, 2001). These defects may be due to impairment of calcium-regulated signal transduction, but the S1P₂ pathways involved in neuronal excitability have not yet been determined (An *et al.*, 1999).

In zebrafish, a single-point mutation in the S1P₂-related *mil* gene leads to abnormal heart development (Kupperman *et al.*, 2000), however, this defect is not recapitulated in S1P₂ knockout mice (Ishii *et al.*, 2002).

S1P levels are up-regulated in the airways of asthmatic patients following allergen exposure. Cross-linking of IgE receptors on mast cells activates SPHK1 and increases S1P levels. Activation of S1P₂, and to a lesser extent S1P₁, promotes degranulation and chemotaxis of mast cells (Jolly *et al.*, 2002; 2004). Also, airway SMC express S1P₁₋₄, and they could modulate the SMC contraction and proliferation through the G_{12/13} and G_{i/o} pathways (Jolly *et al.*, 2002).

S1P₃

In mice, *S1pr3* is highly expressed in heart, lung, spleen, kidney, intestine, diaphragm and certain cartilaginous regions (Ishii *et al.*, 2001). LPA and S1P have vaso-regulatory functions, such as regulation of heart rate, blood pressure, platelet aggregation and smooth muscle contraction (Siess *et al.*, 2000; Karliner, 2004). HDL, which includes S1P as a component, induces vasodilation, in part, by activation of Akt through S1P₃ (Levkau *et al.*, 2004; Nofer *et al.*, 2004). Importantly, in an *in vivo* ischemia/reperfusion (I/R) mouse model of cardiac injury, HDL, and to a greater extent S1P, protected the heart from injury. HDL and S1P reduced infarction size by inhibiting inflammation caused by polymorphonuclear leukocyte recruitment and cardiomyocyte apoptosis in a NO-dependent manner (Theilmeier *et al.*, 2006). In another I/R mouse study, it was shown that infarct size is significantly increased in mice lacking both *S1pr2* and *S1pr3*, but not in mice deficient in only one of these receptors. Furthermore, S1P-induced cardiomyocyte Akt activa-

tion was only ablated when both receptors were deleted, suggesting a redundant protective role for *S1pr2* and *S1pr3* (Means *et al.*, 2007). These studies demonstrated that vasorelaxation, myocardial cell survival, and protection from ischemic damage are mediated by the S1P₃-Akt-eNOS/NO pathway (Levkau *et al.*, 2004; Nofer *et al.*, 2004; Theilmeier *et al.*, 2006; Means *et al.*, 2007). S1P₃ influences on cardiac fibrosis (Takuwa *et al.*, 2009) and myofibroblasts have also been reported (Keller *et al.*, 2007; Niessen *et al.*, 2008).

S1P₄

S1P₄ gene expression is enriched in lymphoid tissues, including immune system cells (Graler *et al.*, 1998; Graeler and Goetzl, 2002). It is also present in SMCs of the human lung (Jolly *et al.*, 2002). Despite wide expression of *S1pr4* throughout the cells of the immune system, no obvious immune cell deficiencies have been reported in *S1pr4* null mutant mice, and the only apparent immune cell abnormality is a perturbation in megakaryocyte cell morphology. However, *in vitro* megakaryocytes from *S1pr4*-deficient mice have reduced platelet formation, and platelet recovery is delayed in an experimental thrombocytopenia model (Golfier *et al.*, 2010). These data suggest that *in vivo* *S1pr4* plays a role in platelet formation; however, functional redundancies with other S1P receptors likely exist. Crosses of *S1pr4* mice with other S1P receptor knockout mice may reveal other roles for *S1pr4* in the immune system.

S1P₅

S1P₅ gene expression is enriched in the spleen and white matter tracts of the CNS, primarily on oligodendrocytes (Im *et al.*, 2000a; Malek *et al.*, 2001; Jaillard *et al.*, 2005). In a recent study using *S1pr5*-constitutive null-mutant mice, it was found that this receptor influences natural killer (NK) cell egress through a T-bet/Tbx21 transcription factor mechanism involving various immunological compartments (Jenne *et al.*, 2009). The functions of *S1pr5* in oligodendrocytes under normal and pathological conditions remain to be determined.

Possible relevance of LP signalling to human diseases

Both LPA and S1P have been shown to act as immunomodulators in the regulation of T cells, B cells and macrophages. Overlapping expression patterns suggest that immune cells are likely regulated by combinations of LP receptors. For example, LPA and S1P acting through LPA_{1,2} and S1P_{2,3}, respectively, may serve as survival factors for T-cells by suppressing Bax (Goetzl *et al.*, 1999b). LPA induces migration and suppression of IL-2 production in unstimulated T cells via LPA₂, however, following T cell stimulation, LPA inhibits cell migration but activates IL-2 production via LPA₁ (Zheng *et al.*, 2000; 2001). LP receptor expression can also dynamically vary with changes in cell activation (Zheng *et al.*, 2000; Graeler and Goetzl, 2002; Rosen *et al.*, 2003).

As mentioned previously, LP signalling has relevance to cancer. One of the better-characterized possible cancer links is to ovarian cancer. LPA elevation in the ascites of patients was reported to elicit growth factor-like activity (Mills *et al.*, 1988), although there is controversy over the reproducibility of this initial report. It has also been shown that LP receptors and the enzymes involved in LPA and S1P metabolism are highly expressed in multiple cancer types (e.g. ovarian cancer and glioblastoma cells have high levels LPA₂ and LPA₃) (Murph *et al.*, 2006). S1P has both positive and negative effects on cancer cell growth (Hong *et al.*, 1999). FTY720 has anti-tumour effects *in vitro* and *in vivo*, and this may be due to a direct effect on tumour cells themselves, and also to indirect effects, like the inhibition of angiogenesis (Azuma *et al.*, 2002; Ho *et al.*, 2005; LaMontagne *et al.*, 2006).

S1P can act to prevent intrinsic-, chemical- and irradiation-induced oocyte apoptosis. S1P injection into the ovarian bursa, ahead of ionizing irradiation, improves the rate of successful pregnancy in irradiated mice (Morita *et al.*, 2000; Tilly, 2001). These data complement effects of LPA signalling on implantation and spermatogenesis (Ye *et al.*, 2005; 2008) and support possible roles in the treatment of human infertility.

LPA and S1P in blood may enter the brain during CNS injury and cause pathological effects. Experimentally induced brain haemorrhage can provide an influx of 1–10 μ M of LPA in the CSF (Tigyi *et al.*, 1995). In cerebral infarction, platelet aggregation can release micromolar concentrations of LPA and can also lead to increased LPA levels in CSF (Eichholtz *et al.*, 1993). Indeed, intracranial injection of LPA or S1P causes astrogliosis *in vivo* (Sorensen *et al.*, 2003). Reactive astrogliosis is a prominent component of CNS injury, including diseases like multiple sclerosis, and recent data support S1P signalling as a therapeutically tractable mechanism in reducing astrogliosis (Choi *et al.*, 2011). Ongoing studies of LP signalling should reveal novel aspects of this therapeutic approach.

LPA pharmacological tools

Over 1% of genes in the human genome are estimated to encode GPCRs (over 1000). Their therapeutic value is proven, but not yet optimally realized because drugs in the clinic target only around 30 of the approximately 400 orphan GPCRs in the genome (Klabunde and Hessler, 2002). Even so, GPCRs are the target of half of all the drugs currently on the market, and remain the focus of major pharmaceutical companies (Klabunde and Hessler, 2002; Gloriam *et al.*, 2009). Chemical tools have been developed towards providing experimental uses and proof-of-concept data. Several LPA receptor agonists or antagonists have been reported, although most show modest selectivity and a relative lack of *in vivo* validation, which must be considered in any experimental usage and particularly for *in vivo* studies.

One LPA receptor agonist is N-acyl ethanolamide phosphate (NAEPA), an LPA analogue that has an ethanol amine backbone (Lynch *et al.*, 1997). To identify receptor selective compounds, a screen with 2-oleoyl LPA, a derivative that had a pyran ring to stabilize the head group, was performed, and

one LPA₁-selective agonist, two LPA₃-selective LPA agonists and one LPA₃-selective antagonist were identified (Tamaruya *et al.*, 2004).

Other LPA receptor antagonists have also been reported. For example, antagonists to both LPA₁ and LPA₃ include VPC-12449, a compound that can protect against LPA₃-mediated renal ischemia-reperfusion injury in a mouse model (Okusa *et al.*, 2003), a natural lipid metabolite, diacylglycerol pyrophosphate (DGPP) (Fischer *et al.*, 2001), and Ki16425, an antagonist with little resemblance to LPA (Ohta *et al.*, 2003) that can inhibit breast cancer cell proliferation and metastasis in mice (Boucharaba *et al.*, 2006). A unique LPA analogue, diastereoisomeric α -bromophosphonates (BrP-LPA) showed antagonistic activity to LPA₁₋₄, and notably inhibited lysophospholipase D activity of autotaxin at a nanomolar level. The anti-isomer of BrP-LPA showed superior efficacy to paclitaxel in reducing the size and blood vessel density of tumours in a mouse orthotopic breast cancer xenograft model (Zhang *et al.*, 2009). Recently, two oral LPA₁ selective antagonists, with chemical structures having little resemblance to LPA, were reportedly used for treatment of lung fibrosis in a rodent model. One compound, AM095, showed anti-fibrotic activity without affecting wound-healing processes (Swaney *et al.*, 2010, 2011).

S1P pharmacological tools

FTY720 (fingolimod) is the best-characterized S1P receptor tool and deserves special consideration (Brinkmann, 2009; Brinkmann *et al.*, 2010; Chun and Hartung, 2010). The US Food and Drug Administration recently approved FTY720 (fingolimod) as an orally active immunomodulatory drug for the treatment of relapsing forms of multiple sclerosis (Novartis). It binds 4 of the 5 identified S1P receptors (S1P₁ and S1P₃₋₅) with high affinity (0.3–3.1 nmol·L⁻¹). A unique feature of FTY720 is that, following its *in vivo* phosphorylation, it first binds S1P receptors and transiently activates downstream pathways; however with continued exposure, it down-regulates the S1P receptor by irreversible internalization and proteasomal degradation (Graler and Goetzl, 2004; Oo *et al.*, 2007). Therefore, FTY720 produces S1P receptor functional antagonism. FTY720 was initially reported to originate from the fungal species known as *Cordyceps*, part of the larger division *Ascomycota* (*Ascomycetes*) in 1995 (Adachi *et al.*, 1995; Suzuki *et al.*, 1996).

Another S1P₁ agonist, AAL-(R), is a non-selective S1P receptor agonist with structural and functional similarities to FTY720 (Brinkmann *et al.*, 2002; Rosen *et al.*, 2003). An S1P₁ partially selective agonist, KRP-203, sequesters circulating lymphocytes into peripheral lymphoid organs (Shimizu *et al.*, 2005), and prevents allograft rejection, but does not affect S1P₃ signalling (Fujishiro *et al.*, 2006). KRP203 (S1P₁ > S1P₃) is currently in Phase II clinical trials for the treatment of subacute cutaneous lupus erythematosus (Novartis). An S1P₁-specific antagonist called W146 can induce loss of capillary integrity (Sanna *et al.*, 2006). SEW2871 and AUY954 are S1P₁ specific agonists and have been shown to functionally prevent lymphocyte egress and inhibit allograft rejection, respectively (Sanna *et al.*, 2004; Pan *et al.*, 2006). AUY954 inhibits receptor recycling following internaliza-

tion, similar to phosphorylated FTY720, thus acting as a functional antagonist for S1P₁ (Choi *et al.*, 2011). These data suggest that at least some FTY720-related agonists can also remove receptors from further agonism, thus producing functional antagonism, as described above.

Aside from mild bradycardia, FTY720 produces few undesirable side effects in humans. In mice, bradycardia is mediated through S1P₃; however, several unpublished reports in primates, including humans, using S1P₁-selective antagonists show that it is mediated through S1P₁ (Chun and Hartung, 2010). The mechanism through which FTY720 operates in multiple sclerosis remains unclear, but likely involves both immunological as well as CNS effects (Chun, 2007; Choi *et al.*, 2011), and this remains an active research area. FTY720 represents the first generation of LP receptor modulators that may have therapeutic value. Other data concerning the efficacy of FTY720 administration for the treatment of type I diabetes, uveoretinitis, thyroiditis, myocarditis, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis in animal models have been reported (Suzuki *et al.*, 1998; Hozumi *et al.*, 1999; Kurose *et al.*, 2000; Matsuura *et al.*, 2000; Okazaki *et al.*, 2002; Fujino *et al.*, 2003; Webb *et al.*, 2004).

For the other S1P receptors, JTE-013 is an S1P₂ specific antagonist (Yokoo *et al.*, 2004). Recently, it was reported that JTE-013 ameliorates pancreatic Beta cell failure in a mouse diabetes model (Imasawa *et al.*, 2010). In addition, there are a number of agonists/antagonists that have been described with varying affinities for the different receptor subtypes (Im *et al.*, 2001; Clemens *et al.*, 2003; 2004; Davis *et al.*, 2005).

Several oral-S1P lyase inhibitors have been developed and clinical trials for the treatment of rheumatoid arthritis have begun. These compounds can increase tissue S1P levels predominantly in lymphoid tissue without other overt physiological effects in rodents. Human clinical trials for the S1P lyase inhibitor LX2931 are being pursued (Bagdanoff *et al.*, 2010).

Another way to inhibit S1P signalling may be through the use of S1P specific monoclonal antibodies. Anti-S1P mAbs have been reported to arrest tumour-associated angiogenesis in a mouse xenograft model (Visentin *et al.*, 2006). Validation of the mechanism and efficacy profile await further study.

Current and future efforts to modulate LP signalling should provide attractive and tractable tools and potentially drugs for the treatment of medically important diseases (Chun and Rosen, 2006; Delgado *et al.*, 2007; Herr and Chun, 2007).

Acknowledgements

This work was supported by grants from the National Institutes of Health (MH051699, NS048478, HD050685, DA019674, DC009505) to Jerold Chun.

Conflicts of interest

Jerold Chun has been a consultant for Novartis and a Scientific Advisory Board member for Amira Pharmaceuticals. Tetsuji Mutoh and Richard Rivera have no conflict of interest.

References

- Adachi K, Kohara T, Nakao N, Arita M, Chiba K, Mishina T *et al.* (1995). Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. *Bioorg Med Chem Lett* 5: 853–856.
- Allende ML, Yamashita T, Proia RL (2003). G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. *Blood* 102: 3665–3667.
- Allende ML, Dreier JL, Mandala S, Proia RL (2004a). Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. *J Biol Chem* 279: 15396–15401.
- Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G *et al.* (2004b). Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. *J Biol Chem* 279: 52487–52492.
- An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, Goetzl EJ (1997). Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. *FEBS Lett* 417: 279–282.
- An S, Bleu T, Hallmark OG, Goetzl EJ (1998). Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. *J Biol Chem* 273: 7906–7910.
- An S, Bleu T, Zheng Y (1999). Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. *Mol Pharmacol* 55: 787–794.
- Anliker B, Chun J (2004a). Cell surface receptors in lysophospholipid signaling. *Semin Cell Dev Biol* 15: 457–465.
- Anliker B, Chun J (2004b). Lysophospholipid G protein-coupled receptors. *J Biol Chem* 279: 20555–20558.
- Aoki J (2004). Mechanisms of lysophosphatidic acid production. *Semin Cell Dev Biol* 15: 477–489.
- Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y *et al.* (2002). Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. *Cancer Res* 62: 1410–1419.
- Bachner D, Ahrens M, Betat N, Schroder D, Gross G (1999). Developmental expression analysis of murine autotaxin (ATX). *Mech Dev* 84: 121–125.
- Bagdanoff JT, Donoviel MS, Nouraldeem A, Carlsen M, Jessop TC, Tarver J *et al.* (2010). Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). *J Med Chem* 53: 8650–8662.
- Balthasar S, Samulin J, Ahlgren H, Bergelin N, Lundqvist M, Toescu EC *et al.* (2006). Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. *Biochem J* 398: 547–556.
- Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K *et al.* (1999). Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. *J Biol Chem* 274: 27776–27785.
- Benton AM, Gerrard JM, Michiel T, Kindom SE (1982). Are lysophosphatidic acids or phosphatidic acids involved in stimulus activation coupling in platelets? *Blood* 60: 642–649.

- Berdyshev EV, Gorshkova IA, Garcia JG, Natarajan V, Hubbard WC (2005). Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. *Anal Biochem* 339: 129–136.
- Bielawski J, Szulc ZM, Hannun YA, Bielawska A (2006). Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. *Methods* 39: 82–91.
- Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O (2006). The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. *Proc Natl Acad Sci USA* 103: 9643–9648.
- Brindley DN, Pilquil C (2009). Lipid phosphate phosphatases and signaling. *J Lipid Res* 50 Suppl.: S225–S230.
- Brinkmann V (2009). FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. *Br J Pharmacol* 158: 1173–1182.
- Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R *et al.* (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J Biol Chem* 277: 21453–21457.
- Brinkmann V, Cyster JG, Hla T (2004). FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. *Am J Transplant* 4: 1019–1025.
- Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G *et al.* (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* 9: 883–897.
- Castilla-Ortega E, Sanchez-Lopez J, Hoyo-Becerra C, Matas-Rico E, Zambrana-Infantes E, Chun J *et al.* (2010). Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor. *Neurobiol Learn Mem* 94: 73–82.
- Chae SS, Proia RL, Hla T (2004). Constitutive expression of the S1P1 receptor in adult tissues. *Prostaglandins Other Lipid Mediat* 73: 141–150.
- Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T *et al.* (2010). LPA receptors: subtypes and biological actions. *Annu Rev Pharmacol Toxicol* 50: 157–186.
- Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K *et al.* (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. *Proc Natl Acad Sci USA* 108: 751–756.
- Chun J (2007). Immunology. The sources of a lipid conundrum. *Science* 316: 208–210.
- Chun J, Hartung HP (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. *Clin Neuropharmacol* 33: 91–101.
- Chun J, Rosen H (2006). Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. *Curr Pharm Des* 12: 161–171.
- Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH (2010). International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. *Pharmacol Rev* 62: 579–587.
- Clemens JJ, Davis MD, Lynch KR, Macdonald TL (2003). Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. *Bioorg Med Chem Lett* 13: 3401–3404.
- Clemens JJ, Davis MD, Lynch KR, Macdonald TL (2004). Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective S1P4 receptor agonists. *Bioorg Med Chem Lett* 14: 4903–4906.
- Contos JJ, Chun J (2000). Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. *Genomics* 64: 155–169.
- Contos JJ, Chun J (2001). The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern. *Gene* 267: 243–253.
- Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chu J (2000a). Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. *Proc Natl Acad Sci USA* 97: 13384–13389.
- Contos JJ, Ishii I, Chun J (2000b). Lysophosphatidic acid receptors. *Mol Pharmacol* 58: 1188–1196.
- Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S *et al.* (2002). Characterization of lpA(2) (Edg4) and lpA(1)/lpA(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpA(2). *Mol Cell Biol* 22: 6921–6929.
- van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH (1989). Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. *Cell* 59: 45–54.
- Croset M, Brossard N, Polette A, Lagarde M (2000). Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. *Biochem J* 345 (Pt. 1): 61–67.
- Das AK, Hajra AK (1989). Quantification, characterization and fatty acid composition of lysophosphatidic acid in different rat tissues. *Lipids* 24: 329–333.
- Davis MD, Clemens JJ, Macdonald TL, Lynch KR (2005). Sphingosine 1-phosphate analogs as receptor antagonists. *J Biol Chem* 280: 9833–9841.
- Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G (2007). Chemical tools to investigate sphingolipid metabolism and functions. *ChemMedChem* 2: 580–606.
- Diao H, Xiao S, Cui J, Chun J, Xu Y, Ye X (2010). Progesterone receptor-mediated up-regulation of transthyretin in preimplantation mouse uterus. *Fertil Steril* 93: 2750–2753.
- Ding WG, Toyoda F, Ueyama H, Matsuura H (2011). Lysophosphatidylcholine enhances I(Ks) currents in cardiac myocytes through activation of G protein, PKC and Rho signaling pathways. *J Mol Cell Cardiol* 50: 58–65.
- Dubin AE, Herr DR, Chun J (2010). Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. *J Neurosci* 30: 7300–7309.
- Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS *et al.* (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. *Pain* 132: 237–251.
- Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH (1993). The bioactive phospholipid lysophosphatidic acid is released from activated platelets. *Biochem J* 291: 677–680.
- Estivill-Torrus G, Llebreg-Zayas P, Matas-Rico E, Santin L, Pedraza C, De Diego I *et al.* (2008). Absence of LPA1 signaling results in defective cortical development. *Cereb Cortex* 18: 938–950.

- Etienne-Manneville S, Hall A (2002). Rho GTPases in cell biology. *Nature* 420: 629–635.
- Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL *et al.* (2001). Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. *Mol Pharmacol* 60: 776–784.
- Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S *et al.* (2003). Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. *J Pharmacol Exp Ther* 305: 70–77.
- Fujishiro J, Kudou S, Iwai S, Takahashi M, Hakamata Y, Kinoshita M *et al.* (2006). Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. *Transplantation* 82: 804–812.
- Fukuda Y, Kihara A, Igarashi Y (2003). Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. *Biochem Biophys Res Commun* 309: 155–160.
- Fukushima N, Weiner JA, Chun J (2000). Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. *Dev Biol* 228: 6–18.
- Gardell SE, Dubin AE, Chun J (2006). Emerging medicinal roles for lysophospholipid signaling. *Trends Mol Med* 12: 65–75.
- Gloriam DE, Foord SM, Blaney FE, Garland SL (2009). Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. *J Med Chem* 52: 4429–4442.
- Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M *et al.* (2006). G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. *Can J Physiol Pharmacol* 84: 287–297.
- Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR *et al.* (1999a). Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. *Cancer Res* 59: 5370–5375.
- Goetzl EJ, Kong Y, Mei B (1999b). Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. *J Immunol* 162: 2049–2056.
- Golfier S, Kondo S, Schulze T, Takeuchi T, Vassileva G, Achtman AH *et al.* (2010). Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4. *FASEB J* 24: 4701–4710.
- Graeler M, Goetzl EJ (2002). Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. *FASEB J* 16: 1874–1878.
- Graler MH, Goetzl EJ (2002). Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. *Biochim Biophys Acta* 1582: 168–174.
- Graler MH, Goetzl EJ (2004). The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. *FASEB J* 18: 551–553.
- Graler MH, Bernhardt G, Lipp M (1998). EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. *Genomics* 53: 164–169.
- Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R *et al.* (2004). Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. *J Biol Chem* 279: 17634–17639.
- Hama K, Aoki J, Bandoh K, Inoue A, Endo T, Amano T *et al.* (2006). Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. *Life Sci* 79: 1736–1740.
- Hama K, Aoki J, Inoue A, Endo T, Amano T, Motoki R *et al.* (2007). Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. *Biol Reprod* 77: 954–959.
- Hanel P, Andreani P, Graler MH (2007). Erythrocytes store and release sphingosine 1-phosphate in blood. *FASEB J* 21: 1202–1209.
- Hecht JH, Weiner JA, Post SR, Chun J (1996). Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. *J Cell Biol* 135: 1071–1083.
- Herr DR, Chun J (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. *Curr Drug Targets* 8: 155–167.
- Herr DR, Grillet N, Schwander M, Rivera R, Muller U, Chun J (2007). Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. *J Neurosci* 27: 1474–1478.
- Herr KJ, Herr DR, Lee CW, Noguchi K, Chun J (2011). Stereotyped fetal brain disorganization is induced by hypoxia and requires LPA1 signaling. *Proc Natl Acad Sci USA* (in press).
- Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST (2005). Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. *Mol Cancer Ther* 4: 1430–1438.
- Hong G, Baudhuin LM, Xu Y (1999). Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. *FEBS Lett* 460: 513–518.
- Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K *et al.* (2009). LPA receptor 2 mediates LPA-induced endometrial cancer invasion. *Gynecol Oncol* 112: 215–223.
- Hozumi Y, Kobayashi E, Miyata M, Fujimura A (1999). Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. *Life Sci* 65: 1739–1745.
- Im DS, Heise CE, Ancellin N, O'Dowd BF, Shei GJ, Heavens RP *et al.* (2000a). Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *J Biol Chem* 275: 14281–14286.
- Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D *et al.* (2000b). Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. *Mol Pharmacol* 57: 753–759.
- Im DS, Clemens J, Macdonald TL, Lynch KR (2001). Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine1-phosphate receptors. *Biochemistry* 40: 14053–14060.
- Imasawa T, Koike K, Ishii I, Chun J, Yatomi Y (2010). Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells. *Biochem Biophys Res Commun* 392: 207–211.
- Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H (2004). Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. *Nat Med* 10: 712–718.
- Inoue M, Yamaguchi A, Kawakami M, Chun J, Ueda H (2006). Loss of spinal substance P pain transmission under the condition of LPA1 receptor-mediated neuropathic pain. *Mol Pain* 2: 25.

- Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H (2008). Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. *Neuroscience* 152: 296–298.
- Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ *et al.* (2001). Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. *J Biol Chem* 276: 33697–33704.
- Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA *et al.* (2002). Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. *J Biol Chem* 277: 25152–25159.
- Ishii I, Fukushima N, Ye X, Chun J (2004). Lysophospholipid receptors: signaling and biology. *Annu Rev Biochem* 73: 321–354.
- Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G *et al.* (2005). Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. *J Neurosci* 25: 459–469.
- Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP *et al.* (2009). T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. *J Exp Med* 206: 2469–2481.
- Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S (2002). The roles of sphingosine-1-phosphate in asthma. *Mol Immunol* 38: 1239–1245.
- Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J *et al.* (2004). Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. *J Exp Med* 199: 959–970.
- Karliner JS (2004). Mechanisms of cardioprotection by lysophospholipids. *J Cell Biochem* 92: 1095–1103.
- Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH *et al.* (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. *Am J Pathol* 170: 281–292.
- Kharel Y, Lee S, Snyder AH, Sheasley-O'Neill SL, Morris MA, Setiady Y *et al.* (2005). Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. *J Biol Chem* 280: 36865–36872.
- Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J (2003). Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. *Nat Neurosci* 6: 1292–1299.
- Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J *et al.* (2004). Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. *Breast Cancer Res* 6: R640–R646.
- Klabunde T, Hessler G (2002). Drug design strategies for targeting G-protein-coupled receptors. *Chembiochem* 3: 928–944.
- Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S (1998). Molecular cloning and functional characterization of murine sphingosine kinase. *J Biol Chem* 273: 23722–23728.
- Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL *et al.* (2007). Deafness and stria vascularis defects in S1P2 receptor-null mice. *J Biol Chem* 282: 10690–10696.
- Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S *et al.* (2006). Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. *J Pharmacol Exp Ther* 318: 619–628.
- Kupperman E, An S, Osborne N, Waldron S, Stainier DY (2000). A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. *Nature* 406: 192–195.
- Kurose S, Ikeda E, Tokiwa M, Hikita N, Mochizuki M (2000). Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. *Exp Eye Res* 70: 7–15.
- LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T *et al.* (2006). Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. *Cancer Res* 66: 221–231.
- Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzelev R *et al.* (1998). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science* 279: 1552–1555.
- Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006). GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. *J Biol Chem* 281: 23589–23597.
- Lee CW, Rivera R, Dubin AE, Chun J (2007a). LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. *J Biol Chem* 282: 4310–4317.
- Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T *et al.* (2007b). Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. *Proc Natl Acad Sci USA* 104: 13732–13737.
- Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A *et al.* (2008). Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. *Mol Biol Cell* 19: 5435–5445.
- Lefkowitz RJ, Shenoy SK (2005). Transduction of receptor signals by beta-arrestins. *Science* 308: 512–517.
- Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O *et al.* (2004). High-density lipoprotein stimulates myocardial perfusion in vivo. *Circulation* 110: 3355–3359.
- Liu H, Sugiyama M, Nava VE, Edsall LC, Kono K, Poulton S *et al.* (2000). Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. *J Biol Chem* 275: 19513–19520.
- Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, Yang VW *et al.* (2009). The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. *Gastroenterology* 136: 1711–1720.
- Lin ME, Herr DR, Chun J (2010). Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. *Prostaglandins Other Lipid Mediat* 91: 130–138.
- Lynch KR, Hopper DW, Carlisle SJ, Catalano JG, Zhang M, MacDonald TL (1997). Structure/activity relationships in lysophosphatidic acid: the 2-hydroxyl moiety. *Mol Pharmacol* 52: 75–81.
- MacLennan AJ, Browe CS, Gaskin AA, Lado DC, Shaw G (1994). Cloning and characterization of a putative G-protein coupled receptor potentially involved in development. *Mol Cell Neurosci* 5: 201–209.
- MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR *et al.* (2001). An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. *Eur J Neurosci* 14: 203–209.
- MacLennan AJ, Benner SJ, Andringa A, Chaves AH, Rosing JL, Vesey R *et al.* (2006). The S1P2 sphingosine 1-phosphate receptor is essential for auditory and vestibular function. *Hear Res* 220: 38–48.

- Malek RL, Toman RE, Edsall LC, Wong S, Chiu J, Letterle CA *et al.* (2001). Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. *J Biol Chem* 276: 5692–5699.
- Matas-Rico E, Garcia-Diaz B, Llebreg-Zayas P, Lopez-Barroso D, Santin L, Pedraza C *et al.* (2008). Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. *Mol Cell Neurosci* 39: 342–355.
- Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V *et al.* (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature* 427: 355–360.
- Matsuura M, Imayoshi T, Chiba K, Okumoto T (2000). Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. *Inflamm Res* 49: 404–410.
- Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I *et al.* (2007). Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* 292: H2944–H2951.
- Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vadrine C *et al.* (2008). FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. *Neurology* 71: 1261–1267.
- Meyer zu Heringdorf D, Jakobs KH (2007). Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. *Biochim Biophys Acta* 1768: 923–940.
- Mills GB, May C, McGill M, Roifman CM, Mellors A (1988). A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. *Cancer Res* 48: 1066–1071.
- Min JK, Yoo HS, Lee EY, Lee WJ, Lee YM (2002). Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. *Anal Biochem* 303: 167–175.
- Moolenaar WH, van Meeteren LA, Giepmans BN (2004). The ins and outs of lysophosphatidic acid signaling. *Bioessays* 26: 870–881.
- Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A *et al.* (2000). Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. *Nat Med* 6: 1109–1114.
- Morris AJ, Selim S, Salous A, Smyth SS (2009). Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. *Trends Cardiovasc Med* 19: 135–140.
- Moumtzi A, Trenker M, Flicker K, Zenzmaier E, Saf R, Hermetter A (2007). Import and fate of fluorescent analogs of oxidized phospholipids in vascular smooth muscle cells. *J Lipid Res* 48: 565–582.
- Murata N, Sato K, Kon J, Tomura H, Okajima F (2000). Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. *Anal Biochem* 282: 115–120.
- Murph M, Tanaka T, Liu S, Mills GB (2006). Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. *Clin Cancer Res* 12: 6598–6602.
- Nagai J, Uchida H, Matsushita Y, Yano R, Ueda M, Niwa M *et al.* (2010). Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. *Mol Pain* 6: 78.
- Neves SR, Ram PT, Iyengar R (2002). G protein pathways. *Science* 296: 1636–1639.
- Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J *et al.* (2008). Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. *Nature* 452: 654–658.
- Nofer JR, van der Giet M, Tolle M, Wolinska I, Lipinski K, Baba HA *et al.* (2004). HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J Clin Invest* 113: 569–581.
- Noguchi K, Ishii S, Shimizu T (2003). Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. *J Biol Chem* 278: 25600–25606.
- Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY *et al.* (2008). Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. *J Biol Chem* 283: 21054–21064.
- Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J *et al.* (2003). Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. *Mol Pharmacol* 64: 994–1005.
- Ohuchi H, Hamada A, Matsuda H, Takagi A, Tanaka M, Aoki J *et al.* (2008). Expression patterns of the lysophospholipid receptor genes during mouse early development. *Dev Dyn* 237: 3280–3294.
- Okajima F (2002). Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? *Biochim Biophys Acta* 1582: 132–137.
- Okazaki H, Ishizaka N, Sakurai T, Kurokawa K, Goto K, Kumada M *et al.* (1993). Molecular cloning of a novel putative G protein-coupled receptor expressed in the cardiovascular system. *Biochem Biophys Res Commun* 190: 1104–1109.
- Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T *et al.* (2002). Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. *J Rheumatol* 29: 707–716.
- Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, Lynch KR (2003). Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 285: F565–F574.
- Olivera A, Rosenthal J, Spiegel S (1994). Sphingosine kinase from Swiss 3T3 fibroblasts: a convenient assay for the measurement of intracellular levels of free sphingoid bases. *Anal Biochem* 223: 306–312.
- Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR *et al.* (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. *J Biol Chem* 282: 9082–9089.
- Pages C, Simon MF, Valet P, Saulnier-Blache JS (2001). Lysophosphatidic acid synthesis and release. *Prostaglandins Other Lipid Mediat* 64: 1–10.
- Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D *et al.* (2006). A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. *Chem Biol* 13: 1227–1234.
- Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y *et al.* (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. *Science* 316: 295–298.

- Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K *et al.* (2008). G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. *Nat Genet* 40: 329–334.
- Pierce KL, Premont RT, Lefkowitz RJ (2002). Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* 3: 639–650.
- Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P *et al.* (2007). LPA1 receptor activation promotes renal interstitial fibrosis. *J Am Soc Nephrol* 18: 3110–3118.
- Pyne NJ, Waters CM, Long JS, Moughal NA, Tigyi G, Pyne S (2007). Receptor tyrosine kinase-G-protein coupled receptor complex signaling in mammalian cells. *Adv Enzyme Regul* 47: 271–280.
- Rivera R, Chun J (2007). Potential therapeutic roles of lysophospholipid signaling in autoimmune-related diseases. *Future Lipidol* 2: 535–545.
- Rivera R, Chun J (2008). Biological effects of lysophospholipids. *Rev Physiol Biochem Pharmacol* 160: 25–46.
- Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG (2003). Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. *Proc Natl Acad Sci USA* 100: 10907–10912.
- Saba JD, Hla T (2004). Point-counterpoint of sphingosine 1-phosphate metabolism. *Circ Res* 94: 724–734.
- Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS *et al.* (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. *J Biol Chem* 279: 13839–13848.
- Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP *et al.* (2006). Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. *Nat Chem Biol* 2: 434–441.
- Santin LJ, Bilbao A, Pedraza C, Matas-Rico E, Lopez-Barroso D, Castilla-Ortega E *et al.* (2009). Behavioral phenotype of *maLPA1*-null mice: increased anxiety-like behavior and spatial memory deficits. *Genes Brain Behav* 8: 772–784.
- Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M *et al.* (2007). HDL-like lipoproteins in cerebrospinal fluid affect neural cell activity through lipoprotein-associated sphingosine 1-phosphate. *Biochem Biophys Res Commun* 359: 649–654.
- Schulte KM, Beyer A, Kohrer K, Oberhauser S, Roher HD (2001). Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor *edg4* in differentiated thyroid cancer. *Int J Cancer* 92: 249–256.
- Schwab SR, Cyster JG (2007). Finding a way out: lymphocyte egress from lymphoid organs. *Nat Immunol* 8: 1295–1301.
- Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG (2005). Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. *Science* 309: 1735–1739.
- Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ *et al.* (2001). Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. *Gynecol Oncol* 81: 291–300.
- Sen S, Smeby RR, Bumpus FM (1968). Antihypertensive effect of an isolated phospholipid. *Am J Physiol* 214: 337–341.
- Shah BH, Catt KJ (2005). Roles of LPA3 and COX-2 in implantation. *Trends Endocrinol Metab* 16: 397–399.
- Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H *et al.* (2004). Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. *Lab Invest* 84: 1352–1362.
- Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S *et al.* (2005). KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. *Circulation* 111: 222–229.
- Shinkuma S, Akiyama M, Inoue A, Aoki J, Natsuga K, Nomura T *et al.* (2010). Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA-PLA1 α in autosomal recessive hypotrichosis. *Hum Mutat* 31: 602–610.
- Siess W, Essler M, Brandl R (2000). Lysophosphatidic acid and sphingosine 1-phosphate: two lipid villains provoking cardiovascular diseases? *IUBMB Life* 49: 167–171.
- Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ *et al.* (2003). Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. *Mol Pharmacol* 64: 1199–1209.
- Spiegel S, Milstien S (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. *Nat Rev Mol Cell Biol* 4: 397–407.
- Stoffel W, Assmann G, Binczek E (1970). Metabolism of sphingosine bases. 13. Enzymatic synthesis of 1-phosphate esters of 4t-sphingenine (sphingosine), sphinganine (dihydrosphingosine), 4-hydroxysphinganine (phytosphingosine) and 3-dehydrosphinganine by erythrocytes. *Hoppe Seylers Z Physiol Chem* 351: 635–642.
- Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F *et al.* (2010). LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. *Blood* 116: 5060–5070.
- Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoye S *et al.* (1996). A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. *Transplantation* 61: 200–205.
- Suzuki K, Yan H, Li XK, Amemiya H, Suzuki S, Hiromitsu K (1998). Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720. *Transplant Proc* 30: 1044–1045.
- Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bunday RA, Prodanovich PC *et al.* (2010). A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. *Br J Pharmacol* 160: 1699–1713.
- Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G *et al.* (2011). Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. *J Pharmacol Exp Ther* 336: 693–700.
- Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z *et al.* (2008). The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. *Nat Med* 14: 45–54.
- Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T *et al.* (2009). S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. *Cardiovasc Res* 85: 484–493.
- Tamaruya Y, Suzuki M, Kamura G, Kanai M, Hama K, Shimizu K *et al.* (2004). Identifying specific conformations by using a carbohydrate scaffold: discovery of subtype-selective LPA-receptor agonists and an antagonist. *Angew Chem Int Ed Engl* 43: 2834–2837.
- Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M *et al.* (2006). Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. *J Biol Chem* 281: 25822–25830.

- Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I *et al.* (2006). High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. *Circulation* 114: 1403–1409.
- Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW (1995). Lysophosphatidic acid alters cerebrovascular reactivity in piglets. *Am J Physiol* 268: H2048–H2055.
- Tilly JL (2001). Commuting the death sentence: how oocytes strive to survive. *Nat Rev Mol Cell Biol* 2: 838–848.
- Tokumura A, Fukuzawa K, Tsukatani H (1978). Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. *Lipids* 13: 572–574.
- Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M *et al.* (2009). Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. *Cell* 138: 1222–1235.
- Van Brocklyn JR, Graler MH, Bernhardt G, Hobson JP, Lipp M, Spiegel S (2000). Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. *Blood* 95: 2624–2629.
- Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG *et al.* (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. *Cancer Cell* 9: 225–238.
- Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J *et al.* (2004). Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. *J Neuroimmunol* 153: 108–121.
- Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W *et al.* (2009). Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. *J Biol Chem* 284: 17304–17319.
- Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J *et al.* (2006). Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. *J Surg Oncol* 93: 30–35.
- Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y *et al.* (2009). Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. *J Biol Chem* 284: 17731–17741.
- Yatomi Y, Welch RJ, Igarashi Y (1997). Distribution of sphingosine 1-phosphate, a bioactive sphingolipid, in rat tissues. *FEBS Lett* 404: 173–174.
- Ye X (2008). Lysophospholipid signaling in the function and pathology of the reproductive system. *Hum Reprod Update* 14: 519–536.
- Ye X, Chun J (2010). Lysophosphatidic acid (LPA) signaling in vertebrate reproduction. *Trends Endocrinol Metab* 21: 17–24.
- Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK *et al.* (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. *Nature* 435: 104–108.
- Ye X, Skinner MK, Kennedy G, Chun J (2008). Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. *Biol Reprod* 79: 328–336.
- Yin H, Chu A, Li W, Wang B, Shelton F, Otero F *et al.* (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. *J Biol Chem* 284: 12328–12338.
- Yokoo E, Yatomi Y, Takafuta T, Osada M, Okamoto Y, Ozaki Y (2004). Sphingosine 1-phosphate inhibits migration of RBL-2H3 cells via S1P2: cross-talk between platelets and mast cells. *J Biochem (Tokyo)* 135: 673–681.
- Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW *et al.* (2011). Lysophosphatidic acid (LPA) signaling as an initiating cause of fetal hydrocephalus. *Sci Translat Med (in press)*.
- Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N *et al.* (2006). Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. *Blood* 107: 1454–1458.
- Zhang G, Contos JJ, Weiner JA, Fukushima N, Chun J (1999). Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. *Gene* 227: 89–99.
- Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J *et al.* (2009). Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. *Cancer Res* 69: 5441–5449.
- Zhao Y, Tong J, He D, Pendyala S, Evgeny B, Chun J *et al.* (2009). Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. *Respir Res* 10: 114.
- Zheng Y, Voice JK, Kong Y, Goetzl EJ (2000). Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. *FASEB J* 14: 2387–2389.
- Zheng Y, Kong Y, Goetzl EJ (2001). Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. *J Immunol* 166: 2317–2322.